The company posted $29.3 million in revenues for the quarter, including $25 million from its tuberculosis business, which grew 17 percent year over year.
Revenues for Roche Diagnostics totaled CHF 6.26 billion for H1, driven primarily by demand for immunodiagnostic solutions.
The company acknowledged the opening up of exclusive insurer contracts may negatively impact revenues next year.
The company's revenues totaled $6.08 billion, up from $4.99 billion during Q2 of 2017.
The firm said that its average revenue per clinical genetic test decreased by almost 4 percent to $318, primarily due to changes in Medicare reimbursement and regulation.
The firm booked $484 million in revenues for Alere rapid diagnostics in the quarter, led by sales for infectious disease and cardiometabolic testing.
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
Based on the growth in test volume and revenue, the company increased its volume and revenue guidance for the year.
Rapid immunoassay product revenues — including sales from the firm's QuickVue, Sofia, and Eye Health products — rose 40 percent year over year.
Total sample-to-answer molecular product revenue for the first quarter of 2018 was $16.5 million, representing 49 percent growth.